Prosecution Insights
Last updated: November 04, 2026
Application No. 18/259,476

METHOD FOR SYNTHESIZING PEPTIDE THIOESTERS AND HEAD-TO-TAIL AMIDE CYCLIC PEPTIDE THEREOF

Non-Final OA §103§112
Filed
Jun 27, 2023
Priority
Dec 28, 2020 — CN 202011579916.9 +1 more
Examiner
LEE, JIA-HAI
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jiangsu Genscript Biotech Co. Ltd.
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
224 granted / 457 resolved
-11.0% vs TC avg
Strong +47% interview lift
Without
With
+46.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
46 currently pending
Career history
523
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
38.2%
-1.8% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
21.8%
-18.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 457 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Groups I, claims 1-12, in the reply filed on 7/10/2026 is acknowledged. The traversal is on the ground(s) that groups I and II share a peptide thioester synthesis method. This is not found persuasive because the shared technical feature does not make a contribution over the cited prior art references (p3, last para) in the restriction requirement dated 6/1/2026. Thus, groups I and II lack unity of invention without a special feature. The requirement is still deemed proper and is therefore made FINAL. Claims 13-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 7/10/2026. Claim Status Claims 1-16 are pending. Claims 13-16 are withdrawn as being directed to a non-elected invention, the election having been made on 7/10/2026. Claims 1-12 have been examined. Priority This application is a 371 of PCT/CN2021/141673 filed on 12/27/2021 and claims foreign priority of CHINA 202011579916.9 filed on 12/28/2020. Information Disclosure Statement The information disclosure statement (IDS) submitted on 6/27/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. Specification The disclosure is objected to because of the following informalities: The resolution of synthetic route for peptide thioester disclosed in the SPEC [0010, 0014] is poor; thus, the examiner requests a substitute SPEC to improve resolution of the synthetic route for peptide thioester. Appropriate correction is required. Claim Objections Claims 1-2, 5, 7, and 11 are objected to because of the following informalities: The resolution of synthetic route for peptide thioester in claim 1 is poor thus, the examiner requests amendment of claim 1 to improve resolution of the synthetic route for peptide thioester. Furthermore, claim 1 contains the acronym “TCFH”, and an acronym in the first instance of claims should be expanded upon/spelled out as “N,N,N′,N′-Tetramethylchloroformamidinium hexafluorophosphate” with the acronym indicated in parentheses as (TCFH). The abbreviations can be used thereafter. Similarly, the acronym “Boc” in claim 2 should be revised to tert-butyloxycarbonyl protecting group (Boc) in the first instance. Similarly, the acronym “DIPEA” in claim 5 should be revised to “N,N-Diisopropylethylamine (DIPEA)”. Similarly, the acronym “NMI” in claim 5 should be revised to “N-methylimidazole (NMI)”. Similarly, the acronym “DMF” in claim 7 should be revised to “N,N-Dimethylformamide (DMF)”. Similarly, the acronym “DMSO” in claim 7 should be revised to “Dimethyl sulfoxide (DMSO)”. Similarly, the acronym “DMA” in claim 7 should be revised to “N,N-Dimethylacetamide (DMA)”. Similarly, the acronym “EDT” in claim 11 should be revised to “1,2-ethanedithiol (EDT)”. Similarly, the acronym “TFA” in claim 11 should be revised to “trifluoroacetic acid (DMF)”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9-10 and 12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 9 recites the broad recitation 4 h-24h, and the claim also recites 16 h-24 h, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Similarly, claim 10 recites the broad recitation 20°C-100°C, and the claim also recites 25°C-50°C, which is the narrower statement of the range/limitation. Similarly, claim 12 recites the broad recitation (50-95):(1-12.5):(1-12.5):(l-12.5):(l-12.5), and the claim also recites 87 .5 : 5 : 2.5 : 2.5 : 2.5, which is the narrower statement of the range/limitation. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 1. Claims 1-2, 5-8, and 11-12 are rejected under 35 U.S.C. 103 as being unpatentable over Stawikowski et al. (Curr Protoc Protein Sci. 2002 Feb;CHAPTER:Unit–18.1, previously cited 6/1/2026), Agrigento et al. (Org. Lett. 2014, 16, 3922−3925, cited in IDS), McMechen et al. (Molecules. 2019 May 18;24(10):1919.), Jahani et al. (Tetrahedron Letters 52 (2011) 1260–1264), and Jad et al. (Org. Process Res. Dev. 2017, 21, 365−369). Claim 1 is drawn to a method of synthesizing a peptide thioester as shown follows comprising: Sequentially coupling a resin conjugated amino acid in an order from the C-terminal to the N-terminal according to a target sequence by means of solid-phase synthesis; Cleaving the resin from the resin peptide with an agent to activate a carboxylic acid; Esterification of the activated peptide with p-chlorothiophenol under the action of a coupling agent of TCFH and an alkali in a solvent; and Cleaving the protected groups to generate an esterified peptide. PNG media_image1.png 440 614 media_image1.png Greyscale PNG media_image2.png 334 734 media_image2.png Greyscale Stawikowski et al. teach a solid phase peptide synthesis (SPPS) procedure as shown as follows (Fig 18.1.1). With respect to step (1), Stawikowski et al. show sequentially coupling a resin conjugated amino acid in an order from the C-terminal to the N-terminal according to a target sequence by means of solid-phase synthesis (Fig 18.1.1). With respect to step (2), Stawikowski et al. show cleavage of synthesized peptide from the solid resin to generate the C-terminal carboxylic acid (R = OH). Stawikowski et al. teach cleavage cocktail of reagent K comprising TFA-phenolthioanisole-1,2-ethanedithiol (same as EDT)-H2O at a ratio of 82.5:5:5:2.5:5 (p8, para 1). Stawikowski et al. do not show esterification of the synthesized peptide reaction with p-chlorothiophenol under the action of a coupling agent of TCFH and an alkali in a solvent. PNG media_image3.png 170 658 media_image3.png Greyscale Agrigento et al. show modification of a peptide with p-chlorothiophenol at the C- terminus of a synthetic peptide via a thioester bond for ligation or cyclization (Abstract; p3922, Table 1; p3924, Table 6-7). Agrigento et al. suggest the reaction performed in a basic organic solvent (p3924, Table 6. Cyclization condition screening). Furthermore, McMechen et al. teach optimization a result effective variable, a mixture of N,N,N’,N’-tetramethylchloroformamidinium hexafluorophosphate (TCFH) and N-methylimidazole (NMI), as coupling reagents as for peptide synthesis (p8, Sec 3.7.4) in Table 1 as shown follows, reading on step (3). With respect to step (4), it would be obvious to cleave the protection groups to generate esterified peptide for further modification ligation or cyclization as suggested by Agrigento et al. (p3924, Table 6. Cyclization condition screening). With respect to claim 2, Stawikowski et al. teach use of t-butyloxycarbonyl (Boc) group for Nα protection during SPPS (p2, para 2). Jahani et al. is cited to show the use of di-tert-butyl decarbonate to generate N-Boc protection of the amine group of amino acids known in the art (abstract; p1263, table 2 and scheme 1). With respect to claims 5-6, Agrigento et al. suggest a ratio of an amine donor compound (reading on an amino acid in a peptide) to a thioester donor compound (reading on p-chlorothiophenol) at 1: 1.2 (p3924, Table 4, legend). McMechen et al. suggest a ratio of TCFH to alkaline (NMI) as 3:9 (1:3) in Entry 4 of Table 1, reading on the ratio range in claim 5. Although the combined prior art references did not specify the ratio 1:1.2:1.5:4, the coupling efficiency of a thioester compound to a peptide is a result effective variable that can be optimized within prior art conditions or through routine experimentation. Thus, the cited prior art references are further obvious to the instant claim 6. See MPEP 2144.05(II)(A). With respect to claims 7-8, Stawikowski et al. teach the use of a solvent mixture comprising DMF to reduce racemization (p7, 2nd last para). Jad et al. is further cited as common knowledge known to one of ordinary skill in the art by showing DMF (N,N-dimethylformamide) is the most widely used solvent for Fmoc-SPPS, which is the conventional method of choice for peptide synthesis. It is usually employed for coupling, washing, and Fmoc-removal steps (Abstract). Thus, it would be obvious to optimize the concentration of DMF for different purposes comprising coupling, washing, and Fmoc-removal steps during peptide synthesis. Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05 (II)(A). With respect to claims 11-12, Stawikowski et al. teach cleavage cocktail of reagent K comprising TFA-phenolthioanisole-1,2-ethanedithiol (same as EDT)-H2O at a ratio of 82.5:5:5:2.5:5 (p8, para 1). One of ordinary skill in the art before the effective filing date of this invention would have found it obvious to combine (i) Stawikowski et al. and (ii) Agrigento et al. in view of McMechen et al. because (a) Stawikowski et al. teach a process of peptide synthesis (p12, Fig, 18.1.1), (b) Agrigento et al. teach thioester leaving group can be synthesized to the C-terminus of a synthetic peptide for ligation or cyclization of peptide (p3924-3925, Table 4-7), and (c) McMechen et al. teach the use of N,N,N’,N’-tetramethylchloroformamidinium hexafluorophosphate (TCFH)/N-methylimidazole (NMI) as coupling reagents for peptide synthesis (p8, Sec 3.7.4). The combination would have reasonable expectation of success because all three references teach synthetic peptides. One of ordinary skill in the art before the effective filing date of this invention would have found it further obvious to combine (i) Stawikowski et al. in view of Agrigento et al. McMechen et al. and (ii) Jahani et al. in view of Jad et al. because (a) Stawikowski et al. in view of Agrigento et al. McMechen et al. teach a process of peptide synthesis, (b) Jahani et al. is cited to show the use of di-tert-butyl decarbonate to generate N-Boc protection of the amine group of amino acids used for peptide synthesis known in the art (abstract; p1263, table 2 and scheme 1), and (c) Jad et al. is further cited as common knowledge to show DMF (N,N-dimethylformamide) is the most widely used solvent for Fmoc-SPPS, which is used for coupling, washing, and Fmoc-removal steps during peptide synthesis known in the art (Abstract). The combination would have reasonable expectation of success because (1) the use of di-tert-butyl decarbonate to generate N-Boc protection of the amine group of amino acids used for peptide synthesis and (2) DMF (N,N-dimethylformamide) is the most widely used solvent for coupling, washing, and Fmoc-removal steps during Fmoc-SPPS known in the art. 2. Claims 1-2 and 5-12 are rejected under 35 U.S.C. 103 as being unpatentable over Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. as applied to claims 1-2, 5-8, and 11-12 and further in view of Beutner et al. (Org. Lett. 2018, 20, 4218−4222). Claim 9 is drawn to the coupling reaction in step (3) is performed for a time of 4 h-24 h, Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. teach a process of peptide esterification with p-chlorothiophenol in the presence of N,N,N’,N’-tetramethylchloroformamidinium hexafluorophosphate (TCFH)/N-methylimidazole (NMI) as applied to 1-2, 5-8, and 11-12. Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. do not specify coupling reaction time for the reaction. Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. PNG media_image4.png 226 552 media_image4.png Greyscale Beutner et al. teach the combination of TCFH and NMI to activate a carboxylic acid in favor of nucleophile reaction to form ester and amide bond (p4218, col 2, para 2). Beutner et al. suggest NMI catalyzing nucleophile reaction (esterification or amidation) by forming a transient intermediate of acyl imidazotium in favor of nucleophile reaction by a thiol group to form a thioester bond or by amine to form an amide bond (p4219, Scheme 2). Beutner et al. suggest the nucleophile reaction catalyzed by TCFH and NMI can be performed at room temperature (reading on 20-25°C) in less than 24 hours (p4220, col 1, para 1). Beutner et al. suggest acyl imidazotium mediated nucleophile reaction form a thioester bond or an amide bond is a result effective variable (p4819, Fig 1) that can be optimized within prior art conditions or through routine experimentation, reading on claims 9-10. See MPEP 2144.05(II)(A). One of ordinary skill in the art before the effective filing date of this invention would have found it obvious to combine (i) Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. with Beutner et al. because (a) Stawikowski et al., Agrigento et al., McMechen et al., Jahani et al., and Jad et al. teach a process of peptide esterification with p-chlorothiophenol in the presence of N,N,N’,N’-tetramethylchloroformamidinium hexafluorophosphate (TCFH)/N-methylimidazole (NMI) and (b) Beutner et al. suggest the nucleophile reaction catalyzed by TCFH and NMI is a result effective variable that can be performed at room temperature (reading on 20-25°C) in less than 24 hours (p4220, col 1, para 1). The combination would have reasonable expectation of success because nucleophile reaction catalyzed by TCFH and NMI can be used for a thiol group to form a thioester bond or for an amine to form an amide bond as suggested by Beutner et al. (p4219, Scheme 2). Examiner’s Note: The examiner did not find the use of 10%-90% trifluoroisopropanol in a dichloromethane solution for cleavage for solid-phase peptide synthesis. The closest prior art reference of Milton et al. teach “An improved solid-phase synthesis of a difficult-sequence peptide using hexafiuoro-2-propanol” (Title). Milton et al. teach 2,2,2-trifluoroethanol and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) able to be used for solid phase peptide synthesis (p193, col 1-2), but Milton et al. did not teach the use of trifluoroisopropanol as a cleavage agent for solid phase peptide synthesis. Thus, claims 3-4 are allowable. Allowable Subject Matter Claims 3-4 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JIA-HAI LEE whose telephone number is (571)270-1691. The examiner can normally be reached Mon-Fri from 9:00 AM to 6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.L/Examiner, Art Unit 1658 08-October-2026 /Melissa L Fisher/ Supervisory Patent Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jun 27, 2023
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758608
STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE
6y 7m to grant Granted Oct 13, 2026
Patent 12741997
SELECTIVE MCL-1 BINDING PEPTIDES
3y 5m to grant Granted Sep 22, 2026
Patent 12729233
ULINASTATIN POLYPEPTIDES
3y 2m to grant Granted Sep 08, 2026
Patent 12721897
PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF
2y 10m to grant Granted Sep 01, 2026
Patent 12703730
LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES
4y 4m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
96%
With Interview (+46.9%)
3y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 457 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month